Drug profile · INN
dyphylline
NEOTHYLLINE
dyphylline (NEOTHYLLINE) is a phosphodiesterase 4 inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Drug details — dyphylline
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
dyphylline (NEOTHYLLINE) is a phosphodiesterase 4 inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Phosphodiesterase 4 inhibitor
Primary target: cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is dyphylline?
dyphylline (NEOTHYLLINE) is a phosphodiesterase 4 inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for dyphylline?
NEOTHYLLINE is a marketed brand name for dyphylline. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dyphylline?
dyphylline has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.